GENMAB A/S (GMAB) Stock
GMAB has an Alpha Score of 48 out of 100 (weak), computed on Oct 31, 2026 from 3 of 4 sub-scores. 4 members of Congress disclosed 12 trades in GMAB since 2020: 7 purchases and 5 sales, most recently Alan Armstrong (purchase, Mar 30, 2026). 5 of the hedge funds AlphaScala tracks reported GMAB in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Renaissance Technologies's at $96.64M. Its trailing P/E ratio is 40.8 and its net margin 19.1% (key statistics as of Nov 6, 2026).
What is GMAB's Alpha Score?
How it works →Alpha Score of 47 reflects weak overall profile with moderate momentum, weak value, moderate quality. Based on 3 of 4 signals – score is capped at 90 until remaining data ingests.
Computed from 3 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Oct 31, 2026
A rules-based research rating, not a recommendation to buy or sell.
Which members of Congress traded GENMAB A/S (GMAB)?
Most recent: Alan Armstrong (purchase, Mar 30, 2026); records start Nov 20, 2020.
| Politician | Trade date | Type | Amount |
|---|---|---|---|
| Alan Armstrong R-OK · Senate | 2026-03-30 | purchase | $1k – $15k |
| Josh Gottheimer D-NJ · House | 2025-01-16 | purchase | $1k – $15k |
| Josh Gottheimer D-NJ · House | 2024-12-16 | sale | $1k – $15k |
| Josh Gottheimer D-NJ · House | 2024-07-19 | purchase | $1k – $15k |
| Josh Gottheimer D-NJ · House | 2024-06-18 | sale | $1k – $15k |
| Josh Gottheimer D-NJ · House | 2023-10-16 | purchase | $1k – $15k |
| Josh Gottheimer D-NJ · House | 2023-09-15 | sale | $1k – $15k |
| Josh Gottheimer D-NJ · House | 2023-07-20 | purchase | $1k – $15k |
From STOCK Act periodic transaction reports. House filings as of Nov 5, 2026. Senate records here end Oct 21, 2026; later Senate trades are not included.
See all GMAB political trades →Which hedge funds own GMAB?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Renaissance Technologies Jim Simons (founder) | 3.52M | $96.64M | -20% |
| Citadel Ken Griffin | 2.48M | $68.02M | NEW |
| Millennium Management Israel Englander | 911K | $25.01M | +15% |
| Marshall Wace | 830K | $22.79M | +5431% |
| Point72 Steve Cohen | 136K | $3.73M | NEW |
13F holdings as of Jun 30, 2026
Explore all tracked funds →What are GMAB's key statistics?
Key statistics as of Nov 6, 2026
How does GMAB's valuation compare with the Healthcare sector?
| Metric | GMAB | Healthcare median | Companies in median |
|---|---|---|---|
| P/E ratio | 40.8 | 28.8 | 111 |
| Net margin | 19.08% | 3.66% | 168 |
| Return on equity | 13.56% | 3.80% | 191 |
Medians over the Healthcare stocks whose key statistics were refreshed in the last 35 days (newest Nov 8, 2026). P/E excludes loss-making companies.
GMAB price chart
Powered by TradingViewWhat does GENMAB A/S do?
Genmab A/S American Depositary Shares represent shares in Genmab A/S, a Copenhagen-based international biotechnology company founded in 1998 that specializes in creating, developing, and commercializing innovative antibody therapeutics to treat cancer and other serious diseases. The company leverages proprietary technologies such as DuoBody, HexaBody, DuoHexaBody, and HexElect to engineer differentiated antibody products. Key marketed therapies include EPKINLY and TEPKINLY for relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma; Tivdak for recurrent or metastatic cervical cancer; Darzalex, partnered with Johnson & Johnson, established as a standard of care for multiple myeloma; Tepezza for thyroid eye disease with Horizon; Kesimpta for relapsing multiple sclerosis with Novartis; Rybrevant for non-small cell lung cancer with Johnson & Johnson; and Epkinly with AbbVie. Genmab A/S also advances a robust pipeline of antibody-based candidates targeting various solid tumors, B-cell malignancies, ovarian cancer, and other oncologic indications, often through strategic partnerships. This focus positions it as a key player in the oncology and immunology segments of the biotech sector.